The stock of Bluejay Diagnostics Inc (NASDAQ: BJDX) has decreased by -11.56 when compared to last closing price of 2.25.Despite this, the company has seen a gain of 13.07% in its stock price over the last five trading days. globenewswire.com reported 2025-06-03 that ACTON, Mass., June 03, 2025 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business and corporate update.
Is It Worth Investing in Bluejay Diagnostics Inc (NASDAQ: BJDX) Right Now?
Moreover, the 36-month beta value for BJDX is 0.42. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BJDX is 1.49M and currently, short sellers hold a 3.12% of that float. On June 10, 2025, BJDX’s average trading volume was 1.81M shares.
BJDX’s Market Performance
The stock of Bluejay Diagnostics Inc (BJDX) has seen a 13.07% increase in the past week, with a 13.07% rise in the past month, and a -52.05% fall in the past quarter. The volatility ratio for the week is 25.22%, and the volatility levels for the past 30 days are at 11.04% for BJDX. The simple moving average for the past 20 days is 11.08% for BJDX’s stock, with a -53.98% simple moving average for the past 200 days.
BJDX Trading at -10.49% from the 50-Day Moving Average
After a stumble in the market that brought BJDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.07% of loss for the given period.
#####
#####
Stock Fundamentals for BJDX
Current profitability levels for the company are sitting at:
- -30.68 for the present operating margin
- 0.25 for the gross margin
The net margin for Bluejay Diagnostics Inc stands at -33.57. The total capital return value is set at -1.67. Equity return is now at value -200.56, with -140.13 for asset returns.
Based on Bluejay Diagnostics Inc (BJDX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -34.39. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -8.11.
Currently, EBITDA for the company is -6.7 million with net debt to EBITDA at 0.46. When we switch over and look at the enterprise to sales, we see a ratio of 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.71.
Conclusion
To wrap up, the performance of Bluejay Diagnostics Inc (BJDX) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
